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ABSTRACT 
Cutaneous melanoma (CM) is the most lethal skin cancer. The Wnt pathway has an impact on 
development, invasion and metastasis of CM, thus likely affecting CM prognosis. Using data 
from a published genome-wide association study (GWAS) from The University of Texas M.D. 
Anderson Cancer Center, we assessed the associations of 19,830 common single-nucleotide 
polymorphisms (SNPs) in 151 Wnt pathway autosomal genes with CM-specific survival (CMSS) 
and then validated significant SNPs in another GWAS from Harvard University. In the 
single-locus analysis, 1,855 SNPs were significantly associated with CMSS at P < 0.05, of which 
547 SNPs were still considered noteworthy after the correction by the false positive report 
probability. In the replication, two SNPs remained significantly associated with CMSS after 
multiple comparison correction. By performing functional prediction and stepwise selection, we 
identified two independent SNPs (i.e., WNT2B rs1175649 G>T and BTRC rs61873997 G>A) that 
showed a predictive role in CMSS, with an effect-allele-attributed hazards ratio [adjHR of 1.99 
(95% confidence interval (CI) = 1.41-2.81, P = 8.10E-05) and 0.61 (0.46-0.80, 3.12E-04), 
respectively]. Collectively, these variants in the Wnt pathway genes may be biomarkers for 
outcomes of CM patients, if validated by larger studies.  
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INTRODUCTION  
Cutaneous melanoma (CM) is one of the most aggressive forms of skin cancers, ranking the fifth 
most common cancer among males and the seventh among females in the United States. In 2016, 
it is estimated that there will be 76,380 new cases of CM and that 10,130 CM patients will die in 
the United States (Siegel et al., 2016). Although the incidence rate of CM has been increasing, 
the mortality rate has remained steady over the past decade (Simard et al., 2012). While the 
increase of CM incidence may partially be attributed to more effective clinical screening (Jemal 
et al., 2011; Purdue et al., 2008), there has been little improvement in the ability to accurately 
assess the prognosis of CM patient. The overall 5-year survival rate of CM patients varies 
substantially, from 97% for localized CM to 65.8% and 15.2% for regional and distant metastasis, 
respectively (Balch et al., 2009).  
Current prognostic tools mainly include clinicopathological variables, such as tumor stage, 
Breslow thickness, and mitotic rate (Balch et al., 2009). However, there is a wide range of 
survival rates among CM patients with similar clinical characteristics, even for the same tumor 
stage (Schramm and Mann, 2011), which possibly results from the heterogeneity of CM and the 
weak specificity of those clinicopathological variables used to evaluate the prognosis of CM 
patients. For example, 30% of CM deaths were found to be attributable to thin lesions that were 
thought to have a good prognosis (Jemal et al., 2011). Therefore, the development of potential 
biomarkers with more prognostic specificity is necessary, which can facilitate the individuality of 
clinical assessment. Genetic variants, such as single-nucleotide polymorphisms (SNPs), have 
been associated with individual variation in susceptibility to and clinical outcome of cancer 
(Dong et al., 2013; Yang et al., 2011). Recently, genome-wide association studies (GWASs) 
have been used to identify genetic variants to be associated with clinical outcomes of pancreatic 
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adenocarcinoma patients with a high statistical power (Wu et al., 2014). 
WNTs are a group of glycoproteins that regulate multiple biological processes, including the 
proliferation, survival, migration and polarity of cells, the specification of cell fate, and the 
self-renewal of stem cells (Clevers and Nusse, 2012; Gomez-Orte et al., 2013). Aberrant activity 
of this pathway plays a role in a number of diseases, such as fibrosis (Chilosi et al., 2003), 
neurodegeneration (Berwick and Harvey, 2012; Inestrosa et al., 2012), metabolic disease 
(Schinner, 2009), and many types of cancer (de La Coste et al., 1998; Palacios and Gamallo, 
1998; Zurawel et al., 1998).  
The Wnt signaling pathway, which is required for melanocyte survival and differentiation 
(Hari et al., 2002; Rabbani et al., 2011), is deregulated in at least 1/3 human melanomas (Rimm 
et al., 1999). The pathway appears to have important roles in melanomagenesis, during both 
tumor initiation (Chien et al., 2009; Delmas et al., 2007) and progression (Damsky et al., 2011; 
Gallagher et al., 2013; Sinnberg et al., 2011). Notably, it has reported that one SNP in WNT3 is 
involved in CM predisposition (Ibarrola-Villava et al., 2015). However, the impact of gene 
variants in the Wnt pathway on CM disease progression has not been systematically tested. Here, 
we hypothesize that genetic variants in the Wnt pathway genes modulate clinical outcome of CM 
patients. To test this hypothesis, we used genotyping data of SNPs in Wnt pathway genes 
extracted from a previously published GWAS of CM from The University of Texas MD 
Anderson Cancer Center (MDACC) (Amos et al., 2011), assessed their associations with the 
survival of CM patients and then validated the SNPs of interest in another GWAS dataset from 
Harvard University.  
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RESULTS 
Patient characteristics  
The final analysis included 858 patients from MDACC and 409 patients from Harvard University 
(Supplementary Table S1 online). All patients with CM were non-Hispanic white. The MDACC 
study included 858 CM patients, whose complete information about clinical variables, risk factor 
data, and GWAS data was described elsewhere (Li et al., 2013). The ages at diagnosis of these 
patients were between 17 and 94 years (mean age ± standard deviation, 52.4 ± 14.4 years), and 
there were more men (496, 57.8%) than women (362, 42.2%). Of these patients, 17.4% (149) had 
been diagnosed with regional/distant metastasis (stage III/IV). The median thickness of localized 
tumors for the MDACC cohort was 1.1 cm. The patients had a median follow-up time of 81.1 
months, during which 133 (15.5%) had died for any reason at the last follow-up. Among these 
deaths, 95 were caused by CM. Univariate analysis indicated that age, sex, regional/distant 
metastasis, Breslow thickness, ulceration, and mitotic rate were significant predictors of 
CM-specific survival (CMSS). In the Harvard study, only age, sex, survival outcome and 
genotype data were available for analysis. Patients had an age range between 34 to 87 years at 
diagnosis (61.1 ± 10.8 years), of whom 66.3% (271) were women. The patients had a relatively 
longer median follow-up time (179.0 months), compared with 175.3 months for MDACC 
patients. During the follow-up, there were 48 (11.5%) patients died of CM, and only age was 
significantly associated with CMSS in univariate analysis of the Harvard dataset. 
Associations between SNPs in the Wnt pathway genes and CMSS 
For the illustrative purpose, Figure 1a provides the flowchart of study design performed in the 
present study. In the discovery using the MDACC study, we first performed multivariate Cox 
proportional hazards regression analyses to assess associations of 19,830 common SNPs (3,151 
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genotyped and 16,679 imputed SNPs) of the Wnt pathway genes with CMSS with adjustments 
for age, sex, regional/distant metastasis, Breslow thickness, ulceration and mitotic rate. As shown 
in Figure 1b, 1,855 SNPs were individually significantly associated with CMSS at P < 0.05 in an 
additive model, of which 547 SNPs were still considered noteworthy after the correction for the 
false positive report probability (FPRP). Among these, three SNPs were validated and remained 
statistically significantly associated with CMSS at P ≤ 0.05 in the Harvard study, including 
rs1175649 in WNT2B (Wnt family member 2B), rs61873997 and rs4919545 in BTRC 
(beta-transducin repeat containing E3 ubiquitin protein ligase). Then, we performed FPRP for 
multiple test correction of the three replicated SNPs in the Harvard dataset and found that 
rs1175649 and rs61873997 were still considered noteworthy after the correction (Supplementary 
Table S2). In the subsequent meta-analysis of these two studies, both of the two SNPs showed 
significant associations with CMSS (Table 1). None of the effects of the two SNPs were 
significantly heterogeneous among the studies (All Phet > 0.05). Using the TCGA dataset of 306 
melanoma cases, we performed the validation analysis for the effects of two tagSNPs (WNT2B 
rs1175649 and BTRC rs61873997) on survival of melanoma patients, in which the follow-up 
information, genotype data, age, and sex were available. Although neither of SNPs was 
statistically significantly associated with OS of melanoma patients, the BTRC rs61873997 A 
allele (HR = 0.81, 95% CI = 0.62–1.05, P = 0.109) appeared to be associated with a protective 
effect on survival of melanoma patients, which is consistent with what we observed in both 
MDACC and Harvard datasets. Because the patients from the TCGA dataset had a relatively 
shorter median follow-up time (59.8 months), a smaller sample size (306 patients) and 
unavailable data of DSS information, additional validation is warranted. However, we did not 
find any evidence for an effect of WNT2B rs1175649 and/or BTRC rs61873997 on survival of 
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non-melanoma skin cancer or other solid tumors. 
Genetic variants in Wnt pathway genes as independent death predictors  
Based on the results of in silico functional prediction using SNPinfo 
(http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm), RegulomeDB (http://www.regulomedb.org/) 
and F-SNP (http://compbio.cs.queensu.ca/F-SNP, Supplementary Table S3 online), we identified 
the two SNPs (i.e., WNT2B rs1175649 G>T and BTRC rs61873997 G>A) as tagSNPs. Initial 
stepwise Cox proportional hazards regression analyses suggested these two tagSNPs as 
independent predictors for CMSS of CM patients (Supplementary Table S4 online). For each of 
the two significant SNPs, we further performed multivariate Cox proportional hazards regression 
analyses to evaluate their effects on death risk with adjustment for other clinicopathological 
covariates (i.e., age, sex, Breslow tumor thickness, regional/distant metastasis, ulceration of 
tumor and tumor cell mitotic rate) for the MDACC dataset but only age and sex for the Harvard 
dataset. In the MDACC study, the risk effect of the WNT2B rs1175649 T allele (adjHR = 1.97; 95% 
CI = 1.26–3.09, P = 0.003) and protective effect of the BTRC rs61873997 A allele (adjHR = 0.62; 
95% CI = 0.44–0.87, P = 0.006) on CM survival were statistically significant in the trend test. In 
the validation using the Harvard study, similar results were obtained for the WNT2B rs1175649 T 
allele (adjHR = 2.03; 95% CI = 1.19-3.46, P = 0.010) and for the BTRC rs61873997 A allele 
(adjHR = 0.58; 95% CI = 0.37–0.92, P = 0.021) (Table 2). To further visualize the HR effects, we 
present Kaplan–Meier survival curves of the associations with CMSS for risk genotypes of 
WNT2B rs1175649 and BTRC rs61873997 in Figure 2a-2d. The regional association results from 
the MDACC GWAS dataset were plotted for WNT2B and BTRC, including the 250 kb regions 
flanking the neighborhoods of these two genes (Supplementary Figure S1 online). 
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Survival of CM patients with unfavorable genotypes 
To better estimate the joint effect of the two tag SNPs on risk of death, we combined the 
unfavorable genotypes (those all associated with an increased death risk) of WNT2B rs1175649 
GT/TT and BTRC rs61873997 GG into one variable (or a genetic score), which we termed the 
‘number of unfavorable genotypes’ (NUG) score. The P value for trend test for a per-unit 
increase in the NUG score was < 0.0001 for CMSS in the MDACC study. In the Harvard study, a 
similar trend was observed in the association of NUGs and CMSS (P = 0.0009, Table 3). 
Prognosis was the worst in patients with a NUG score of 2 for CMSS in the MDACC study 
(adjHR = 3.01; 95% CI = 1.56–5.78, P = 0.001) and the Harvard study (adjHR = 3.84; 95% CI = 
1.74–8.47, P = 0.0008), compared with a NUG score of 0. We next dichotomized all patients into 
a low-risk group (NUG score 0) and a high-risk group (NUG score 1–2). We found that, 
compared with the low-risk group, the high-risk group had a more than 2-fold higher CM-death 
risk in the MDACC study (adjHR = 2.27, 95% CI = 1.44–3.57, P = 0.0004) and the Harvard 
study (adjHR = 2.30, 95% CI = 1.23–4.29, P = 0.009, Table 3). For the illustrative purpose, 
Kaplan–Meier curves of these associations of the NUG score with CMSS are shown in Figure 
2e-2f.  
Stratified analyses of the NUG score as a predictor of survival in CM patients 
We further performed stratified analyses to investigate whether the combined effect of 
unfavorable genotypes on CMSS was modified by the clinical variables factors in MDACC study. 
We found that patients with the high-risk NUG score (1–2), but not the low-risk NUG score (0), 
showed a substantially increased risk of CM death in the presence or absence of concomitant 
clinical variables (e.g., age, sex, regional/distant metastasis, Breslow thickness, ulceration and 
tumor cell mitotic rate), except for three subgroups (male; patients without ulceration; patients 
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with tumor cell mitotic rate ≤ 1/mm2), However, no heterogeneity was observed among all the 
subgroups (Supplementary Table S5 online).  
Genotype-phenotype correlation analyses 
To further understand the molecular mechanisms underlying the observed risk associations with 
the genotypes, we evaluated the correlations between SNPs and their corresponding mRNA 
expression levels in normal cells using the publically available RNA-seq data of lymphoblastoid 
cell lines from 373 European descendants included in the 1000 Genomes Project (Genomes 
Project et al., 2012; Lappalainen et al., 2013). We found that rs1175649 genotype demonstrated a 
significant association with an increased mRNA expression of WNT2B in both additive and 
dominant models (P = 0.006 and P = 0.042, respectively, Figure 3a-b). However, no significant 
correlation was found between rs61873997 genotypes and BTRC mRNA expression (for additive 
model, P = 0.900; for recessive model, P = 0.152; Supplementary Figure S2 online). We further 
performed expression quantitative trait loci (eQTLs) analysis using data from the 
Genotype-Tissue Expression (GTEx) Project (http://www.gtexportal.org/home) (Consortium, 
2013), which includes WNT2B rs1175649 in subcutaneous adipose tissues from 298 donors. It 
was shown that rs1175649 T was associated with a significant increased WNT2B mRNA 
expression level (P = 4.4E-8) in an additive genetic model (Figure 3c), which confirms our initial 
findings. 
DISCUSSION 
In the present study, we found that genetic variants WNT2B rs1175649 and BTRC rs61873997, 
were likely to independently or jointly modulate the survival of CM patients. Moreover, 
rs1175649 was found to influence WNT2B mRNA expression levels. These findings suggest that 
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Wnt pathway gene variants may have biological roles in CM progression, possibly through a 
mechanism of modulating expression of these genes. 
Although the prevalence of the Wnt signaling pathway deregulation in melanoma is known, 
the effect of this deregulation is complex. Several studies have shown that nuclear β-catenin 
levels decrease as melanoma progresses and that this decrease is associated with a poor prognosis 
(Bachmann et al., 2005; Meyer et al., 2012). Conversely, other studies reported that the Wnt  
pathway activation stimulates cell growth (Widlund et al., 2002), bypasses senescence (Delmas et 
al., 2007), promotes tumor cell survival and chemoresistance (Sinnberg et al., 2011), resulting in 
a worsened prognosis (Kielhorn et al., 2003; Murakami et al., 2001). Likewise, β-catenin 
activation in melanocytes might restrict cellular motility and migration and promote lung 
metastasis in the NRAS-driven melanoma murine model (Gallagher et al., 2013). Besides, 
β-catenin activation substantially increases metastasis to the lungs in GEMMs with mutant Braf 
and inactivated Pten, indicating that β-catenin may have conflicting roles in the metastasis of 
melanoma, repressing migration while promoting metastasis (Damsky et al., 2011). Therefore, 
clinical decisions should be made by taking into the consideration the context-dependent role of 
the Wnt signaling in melanoma development. 
In the present study, we found some significant associations of CMSS with genetic variants 
in WNT2B and BTRC. Patients with increasing the NUG score, which represents the combined 
effect of unfavorable genotypes of these genetic variants, had poorer survival. Notably, the effect 
was consistent across different analyses and most subgroup comparisons, supporting a robust 
association of the NUG score with CM survival. Furthermore, we believe that our results are 
likely biologically plausible. The genotype-phenotype correlation indicates that WNT2B 
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expression levels may be modulated by rs1175649, which provides a possible explanation for the 
observed association with CM survival. 
WNT2B is located on chromosome 1p13, participates in the canonical Wnt pathway and 
transduces signals through Frizzled and LRP5/LRP6 receptors, promoting the release of β-catenin 
from the AXIN-APC degradation complex (Korinek et al., 1997). WNT2B has been involved in 
several aspects of tumor biology, including metastatic ability and drug resistance. For example, 
silencing of WNT2B inhibits metastasis and enhances cisplatin sensitivity in ovarian cancer cells 
(Wang et al., 2012); WNT2B has also been shown to be overexpressed in two cisplatin-resistant 
oral cancer cell lines, and the silencing of WNT2B suppresses the proliferation and colony 
forming ability of cancer cells (Li et al., 2015).  
BTRC is located on chromosome 10q24.32. As a cytoplasmic negative regulator of the Wnt 
pathway, BTRC is important for the ubiquitin-mediated degradation of β-catenin by the 
proteasome. Although we could find little prior evidence linking BTRC to CM prognosis, it has 
been shown to influence prognosis in other cancers. For instance, it is reported that 
down-regulation of BTRC were associated with poor prognosis in nasopharyngeal carcinoma 
patients (Yan et al., 2015). Besides, BTRC gene expression levels predicted postoperative 
recurrence of lung cancer in patients (Tseng et al., 2010).  
The current study has several important strengths. A major strength of this study is the 
comprehensive analyses of associations between SNPs in the Wnt pathway genes and CM 
survival using two published GWASs datasets that had strict quality control procedures. In our 
analyses, we adjusted for variables that could confound our observations of a genetic effect on 
CMSS. Although compared with the MDACC survival analysis (with adjustment for age, sex, 
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Breslow thickness, regional/distant metastasis, ulceration and mitotic rate), the adjusted 
information was only available for age and sex in the Harvard study, and no heterogeneity was 
observed in the results from the two studies, which indicates that the observed effect of each SNP 
on CMSS from the two studies is consistent. We also performed the FPRP correction to assess 
the possibility of false-positive associations as a result of multiple testing. Furthermore, the 
pathway-based analysis allowed us to explore the polygenic effects and properly identifying the 
truly functional variants from the available high-dimensional data and also can improve detection 
of the combined effects of these SNPs on survival. Our findings demonstrated the potential 
importance of assessing CM prognosis by combining clinicopathological characteristics with the 
added genetic information.  
However, the present study has some limitations. First, among our participants, treatment 
plans likely varied, and we could not control for the differences in treatment. Nevertheless, 
systemic therapies have had only a modest impact on patient survival, and it is highly unlikely 
that treatment plans varied systematically by germline genotype. We also performed stratified 
analyses by regional/distant metastasis, Breslow thickness, ulceration and mitosis to minimize the 
effect of different treatments. The second caveat is that the prognosis-predicting model was built 
in a US non-Hispanic white population, and therefore its application to different ethnic groups 
requires further investigation and validation. Another limitation is that our analysis did not take 
into account gene-gene interactions that widely exist in cancer. Our ability to perform such an 
evaluation was limited by the sample size and study power, given the relatively limited number 
of outcome events observed in the study population. 
In summary, we performed a comprehensive assessment of genetic variants in genes 
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involved in the Wnt pathway in two independent GWAS datasets, identified two SNPs (WNT2B 
rs1175649 and BTRC rs61873997) that may independently or jointly affect the survival of CM 
patients. However, our findings need to be validated in an independent, larger patient population, 
preferably with different ethnic groups.  
 
MATERIALS AND METHODS 
Study population 
This study contained a discovery dataset (the GWAS dataset from MDACC) and a replication 
dataset [the Nurses’Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) 
from the Harvard University]. The study protocols were approved by Institutional Review Boards 
at both MD Anderson and Brigham and Women’s Hospital with a written informed consent 
obtained from each of the subjects.  
Discovery Dataset  
Participant recruitment and patients' characteristics in the MDACC GWAS study have been 
described elsewhere (Amos et al., 2011; Li et al., 2013). In brief, patients were accrued for a 
hospital-based case-control study of CM at MDACC between March 1998 and August 2008. All 
cases were diagnosed with histologically confirmed cutaneous melanoma. The stage of the 
disease and length of the follow-up were determined from the date of diagnosis. The final 
analysis included 858 patients for whom information for clinicopathological variables was 
available. All individuals provided a written informed consent under an Institutional Review 
Board-approved protocol. The genotype data used in this study can be accessed using the 
National Center for Biotechnology Information (NCBI) Database of Genotypes and Phenotypes 
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(dbGaP; http://www.ncbi.nlm.nih.gov/gap), with the study accession number phs000187.v1.p1. 
The detailed genotyping information and data quality control have been reported (Simard et al., 
2012). Genome-wide imputation was performed using the MACH software program based on 
1000 Genomes Project, phase I V2 CEU data (Li et al., 2010). 
Replication Dataset 
The Harvard dataset consisted of two studies: NHS and HPFS. Sampling, genotyping and quality 
control procedures have been described previously (Song et al., 2012). Information on melanoma 
development was first collected in the 1984 questionnaire and 1986 questionnaire of NHS and 
HPFS, respectively. Eligible cases in both the NHS and HPFS cohorts were participants with 
histopathologically confirmed invasive melanoma, diagnosed at any time after baseline up to the 
2008 follow-up cycle for both cohorts. All subjects were US non-Hispanic white. In the final 
analysis, 409 patients were kept in the data after quality control. Genotyping in the Harvard 
dataset was performed using the Illumina HumanHap610 array. Imputation was performed based 
on genotyped SNPs and haplotype information from phase II HapMap CEU data using the 
program MACH (Biernacka et al., 2009). Only SNPs with imputation quality r2 > 0.8 were 
included, and a total of 1,579,307 SNPs passed through the filter.  
SNP selection for the Wnt pathway analysis 
On the basis of the databases of KEGG (http://www.genome.jp/kegg/) and Biocarta 
(http://www.biocarta.com/), we selected the following 151 Wnt pathway genes that are located on 
autosomes. Common SNPs (minor allele frequency ≥ 0.05, genotyping rate ≥ 95% and Hardy–
Weinberg equilibrium P value ≥ 0.00001) within these genes or their ± 2 kb flanking regions 
were selected for association analysis. As a result, 19,830 common SNPs in the Wnt pathway 
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were extracted from our CM GWAS dataset. For illustrative purposes, a flow chart of detailed 
SNP selection among Wnt pathway genes is shown in Figure 1a. 
Statistical methods 
Further details are available in the Supplementary Materials (online). 
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SUPPLEMENTARY MATERIAL 
Supplementary material is linked to the online version of the paper at http://www.nature.com/jid 
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Table 1.  Combined analysis of two validated SNPs using two published melanoma GWAS datasets 
SNP Allele1 MAF Gene 
MDACC (n=858) 
 
Harvard (n=409) 
 
Combined analysis 
HR (95% CI)2 P2 HR (95% CI)3 P3 
 
Phet I 2 HR  (95% CI)4 P4 
rs1175649 G/T T: 0.11 WNT2B 1.97 (1.26-3.09) 0.003 
 
2.03 (1.19-3.46) 0.010 
 
0.933 0 1.99 (1.41-2.81) 8.10E-05 
rs61873997 G/A A: 0.34 BTRC 0.62 (0.44-0.87) 0.006 
 
0.58 (0.37-0.92) 0.021 
 
0.818 0 0.61 (0.46-0.80) 3.12E-04 
Abbreviations: SNP, single-nucleotide polymorphism; GWAS, genome-wide association studies; MAF, minor allele frequency; MDACC, M.D. Anderson Cancer 
Center; HR: hazards ratio; CI: confidence interval; Phet: P-value for heterogeneity by Cochrane’s Q test; 
1Reference allele/effect allele; 
2Adjusted for age, sex, Breslow’s tumor thickness, regional/distant metastasis, ulceration of tumor and tumor cell mitotic rate; 
3Adjusted for age and sex; 
4Meta-analysis in a fixed-effects model. 
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Table 2. Associations between tagging SNPs in WNT2B and BTRC of the Wnt pathway and CMSS of CM patients in the MDACC Study and the Harvard study 
      
      
Genotype  
MDACC study 
 
Harvard study 
 
All Death (%) HR (95% CI)1 P1 
 
All Death (%) HR (95% CI)2 P2 
WNT2B 
          rs1175649 
         
 
GG 682 68 (10.0) 1.00 
  
321 32 (10.0) 1.00 
 
 
GT 171 27 (15.8) 2.11 (1.32-3.38) 0.002 
 
85 14 (16.5) 1.76 (0.94-3.29) 0.079 
 
TT 5 0 (0.0) -- -- 
 
3 2 (66.7) 7.02 (1.62-30.30) 0.009 
 
Trend test 
  
1.97 (1.26-3.09) 0.003 
   
2.03 (1.19-3.46) 0.010 
 
GT+TT vs GG 
  
2.08 (1.30-3.33) 0.002 
   
1.93 (1.06-3.53) 0.031 
BTRC          
rs61873997 
         
 
GG 367 52 (14.2) 1.00 
  
171 29 (17.0) 1.00 
 
 
GA 391 37 (9.5) 0.60 (0.39-0.93) 0.022 
 
182 14 (7.7) 0.44 (0.23-0.83) 0.011 
 
AA 100 6 (6.0) 0.45 (0.19-1.07) 0.070 
 
56 5 (8.9) 0.50 (0.19-1.29) 0.152 
 
Trend test 
  
0.62 (0.44-0.87) 0.006 
   
0.58 (0.37-0.92) 0.021 
  GA+AA vs GG     0.57 (0.38-0.87) 0.009       0.45 (0.25-0.81) 0.007 
 
       
Abbreviations: SNP, single-nucleotide polymorphism; CMSS, cutaneous melanoma-specific survival; CM, cutaneous melanoma; MDACC, MD Anderson Cancer 
Center; HR: hazards ratio; CI: confidence interval. 
1Adjusted for age, sex, Breslow thickness, regional/distant metastasis, ulceration of tumor and tumor cell mitotic rate. 
2Adjusted for age and sex. 
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Table 3.  HRs for associations between NUGs and CMSS in CM patients of the MDACC study and the Harvard study 
Genotype 
MDACC study 
 
Harvard study 
All Death (%) HR (95% CI)2 P2 
 
All Death (%) HR (95% CI)3 P3 
NUG1 
         
0 393 30 (7.6) 1.00 
  
191 14 (7.3) 1.00 
 
1 387 51 (13.2) 2.12 (1.33-3.40) 0.002 
 
177 23 (13.0) 1.92 (0.99-3.74) 0.055 
2 78 14 (17.9) 3.01 (1.56-5.78) 0.001 
 
41 11 (26.8) 3.84 (1.74-8.47) 0.0008 
Trend test 
   
<0.0001 
    
0.0009 
Dichotomized          
0 393 30 (7.6) 1.00 
  
191 14 (7.3) 1.00 
 
1-2 465 65 (14.0) 2.27 (1.44-3.57) 0.0004 
 
218 34 (15.6) 2.30 (1.23-4.29) 0.009 
Abbreviations: HR, hazards ratio; NUGs, number of unfavorable genotypes; CMSS, cutaneous melanoma-specific survival; CM, cutaneous 
melanoma; MDACC, MD Anderson Cancer Center; CI: confidence interval. 
1Risk genotypes were rs1175649 TT+GT, and rs61873997 GG;  
2Adjusted for age, sex, Breslow thickness, regional/distant metastasis, ulceration of tumor and tumor cell mitotic rate. 
3Adjusted for age and sex. 
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FIGURE LEGENDS 
Figure 1. Screening for SNPs in the Wnt pathway genes. (a) Research workflow. MDACC, 
The University of Texas M.D. Anderson Cancer Center; GWAS, genome-wide association study; 
SNP, single-nucleotide polymorphism; HWE, Hardy Weinberg equilibrium; MAF, minor allele 
frequency. (b) Manhattan plot of associations between 19,830 SNPs and CMSS. There are 1,855 
SNPs with P < 0.05. The blue horizontal line indicates P = 0.05. 
Figure 2. Selected SNPs and survival prediction. (a-b) Kaplan–Meier curves of cutaneous 
melanoma-specific survival (CMSS) stratified by WNT2B rs1175649, assuming a dominant 
model in the MDACC study (a) and in the Harvard study (b). (c-d) Kaplan–Meier curves of 
CMSS stratified by BTRC rs61873997, assuming a dominant model in the MDACC study (c) 
and in the Harvard study (d). (e-f) Kaplan–Meier survival curves of the combined risk genotypes: 
dichotomized groups of the NUGs in the MDACC study (e) and in the Harvard study (f).  
Figure 3. Associations between rs1175649 genotypes and WNT2B mRNA expression levels. 
The expression quantitative trait loci analysis (eQTLs) for WNT2B rs1175649 in 373 Europeans 
from the 1000 Genomes Project in the additive model (a) and in the dominant model (b). (c) The 
expression quantitative trait loci analysis (eQTLs) from the Genotype-Tissue Expression (GTEx) 
project for WNT2B rs1175649 in an additive genetic model. 
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